Partners L P/Ilbiotechnolog... Net Worth

The estimated Net Worth of Partners L P/Ilbiotechnolog... is at least $103 Million dollars as of 21 May 2020. Partners Ilbiotechnolog owns over 2,283,598 units of XOMA Royalty stock worth over $13,029,316 and over the last 9 years Partners sold XOMA stock worth over $89,594,443.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Ilbiotechnolog XOMA stock SEC Form 4 insiders trading

Partners has made over 56 trades of the XOMA Royalty stock since 2016, according to the Form 4 filled with the SEC. Most recently Partners sold 2,283,598 units of XOMA stock worth $13,701,588 on 21 May 2020.

The largest trade Partners's ever made was buying 6,333,333 units of XOMA Royalty stock on 8 February 2018 worth over $18,999,999. On average, Partners trades about 678,164 units every 27 days since 2016. As of 21 May 2020 Partners still owns at least 480,432 units of XOMA Royalty stock.

You can see the complete history of Partners Ilbiotechnolog stock trades at the bottom of the page.

Insiders trading at XOMA Royalty

Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.

What does XOMA Royalty do?

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.

Complete history of Partners Ilbiotechnolog stock trades at Calithera Biosciences Inc, Concert Pharmaceuticals Inc, CTI BioPharma Corp, Cytokinetics Inc, Five Prime Therapeutics Inc, GlycoMimetics Inc, Infinity Pharmaceuticals, Merus N.V, Pieris Pharmaceuticals Inc, Syndax Pharmaceuticals Inc, Xenon Pharmaceuticals Inc, and XOMA Royalty

XOMA Royalty executives and stock owners

XOMA Royalty executives and other stock owners filed with the SEC include:

• James Neal,
  Chief Executive Officer, Director
• Thomas Burns,
  Chief Financial Officer, Senior Vice President - Finance
• James R. Neal,
  CEO & Chairman
• Thomas M. Burns,
  Sr. VP of Fin. & CFO
• Barbara Kosacz,
  Independent Director
• W. Denman Van Ness,
  Independent Chairman of the Board
• Jack Wyszomierski,
  Independent Director
• Joseph Limber,
  Independent Director
• Matthew Perry,
  Independent Director
• Natasha Hernday,
  Director
• Deepshikha Datta,
  Chief Business Officer
• Timothy P Walbert,
  Director
• Peter Barton Hutt,
  Director
• Paul D Rubin,
  VP Clinical Dev. & CMO
• Steven B Engle,
  CEO and President
• Charles J Jr Fisher,
  Director
• Patrick J Zenner,
  Director
• John Varian,
  Director
• Owen Hughes,
  Chief Executive Officer
• Partners L P/Ilbiotechnolog...,
  
• Fred Kurland,
  VP Finance
• Thomas Klein,
  Chief Commercial Officer
• William K Jr Bowes,
  Director
• Bros. Advisors Lp667, L.P.B...,
  
• Bros. Advisors Lpbaker Feli...,
  
• Bros Advisors Llcbaker Feli...,
  
• Patrick J Md Phd Scannon,
  CSMO
• Kelvin Neu,
  Director
• Julianbaker Bros Advisors L...,
  
• J David Ii Boyle,
  VP, Finance, and CFO
• Arthur Md Kornberg,
  Director
• John L Castello,
  Chairman, CEO & President
• James G Andress,
  Director
• Peter B Davis,
  VP, Finance & CFO
• Clarence L Dellio,
  Sr VP, Operations and COO
• Steven C Mendell,
  Director
• Christopher J Margolin,
  VP, General Counsel & Sec'y
• Partners L P/Ilbiotechnolog...,
  
• Heather L Franklin,
  
• Bradley Sitko,
  Chief Investment Officer